For instance, the cetuximab (epidermal growth factor receptor inhibitor) has a better effect than bevacizumab (vascular endothelial growth factor receptor inhibitor) in left-sided CRC patients with wild-type K-RAS, N-RAS and BRAF genes [17]. This evidence concerns the gene NRAS and colorectal carcinoma.